# Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC

> **NCT05768347** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 9 (actual)

## Conditions studied

- Urothelial Carcinoma
- Non-Invasive Bladder Urothelial Carcinoma

## Interventions

- **BIOLOGICAL:** Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL)

## Key facts

- **NCT ID:** NCT05768347
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-10
- **Primary completion:** 2025-10-10
- **Final completion:** 2027-01
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2025-12-04

## Collaborators

- United States Department of Defense

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05768347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05768347, "Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT05768347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*